Jiangsu Hengrui Pharmaceuticals Co Ltd (Jiangsu Hengrui) focuses on the research, development, manufacture, and distribution of novel pharmaceutical products for treating cancer, diabetes, Crohn’s disease, psoriasis, and other diseases. Its product portfolio includes antitumor drugs, cardiovascular medicines, endocrine medicines, antibiotics, large infusion, and other products. Its products are used in the treatment of various therapy areas, including anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, and nervous system diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Jiangsu Hengrui has made innovation the core of its development strategy, investing over US$6,350 million in research and development (R&D) in recent years. The company has established 14 R&D centers globally. The company has also engaged in international collaborations, resulting in 14 out-licensing transactions for its innovative drugs and drug candidates with global partners since 2018. Hengrui's R&D initiatives are supported by a new electronic R&D project management platform that provides intelligent operational management across the entire R&D lifecycle. The company's R&D activities include target identification and validation, molecular discovery and modification, preclinical studies, IND application, clinical trials, and NDA/BLA submissions. The unit leverages a new electronic R&D project management platform to streamline these processes and ensure compliance with global standards. In FY2024, the company spent CNY8,227.9 million on R&D, which, as a percentage of revenue, stood at 29.4% and grew 33.8% YoY. As of December 2024, the company has 23 commercialized new molecular entity drugs and 4 other innovative drugs. It also owns 1,084 issued patents in the Greater China region and 753 issued patents in different jurisdictions, including the US, Europe, and Japan. As of December 2024, Jiangsu Hengrui is conducting approximately 400 clinical trials for over 90 innovative drug candidates and has filed 2,609 patent applications in China. Some of the pipeline products in Phase III clinical trials include SHR-A2009 to treat EGFR-mutated advanced or metastatic non-small cell lung cancer that has failed EGFR TKI therapy; SHR-A1921 to treat Platinum-sensitive recurrent epithelial ovarian cancer as a single Agent or Combination Therapy with carboplatin; SHR-A1904 to treat 2nd-line CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma; SHR-A2102 to treat 2nd/3rd-line locally advanced or metastatic urothelial carcinoma; HR17031 to treat Type 2 diabetes mellitus; HRS-7535 to treat Type 2 diabetes mellitus; HRS9531 to treat Overweight or obesity; SHR-2004 to treat Prevention of venous thromboembolism after knee arthroplasty; SHR-1918 to treat Homozygous familial hypercholesterolemia; SHR6508 to treat Secondary hyperparathyroidism in patients on maintenance hemodialysis with chronic kidney disease; SHR-1819 to treat Atopic dermatitis; SHR-1703 to treat Eosinophilic asthma; HRS-5965 to treat Untreated paroxysmal nocturnal hemoglobinuria; HRS-8427 to treat Complicated urinary tract infection; and SHR7280 to treat Controlled ovarian hyperstimulation.